Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252952 | 0.83 | EPHX1 (0.55) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| Hydrogen Sulfide SCHEMBL9623454 | 0.80 | EPHX1 (0.52) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| SCHEMBL453959 | 0.78 | EPHX1 (0.41) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| SCHEMBL6682496 | 0.76 | EPHX1 (0.48) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| SCHEMBL2581115 | 0.75 | EPHX1 (0.39) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| SCHEMBL11691827 | 0.75 | ALDH1A1 (0.55) | CYP1A2ALDH1A1SRRNPC1RAB9A | |
| SCHEMBL12708159 | 0.74 | TRPA1 (0.54) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| SCHEMBL1552921 | 0.74 | TRPA1 (0.54) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| SCHEMBL10457665 | 0.74 | EPHX1 (0.46) | EPHX1TSHRTAAR1SLC6A2SIGMAR1 | |
| SCHEMBL1975377 | 0.74 | TRPA1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118777449-B | Method for separating and detecting related substances in benzyl-2-bromoethyl ether serving as starting material of ubenimex based on gas chromatography and liquid chromatography | 山东泰合医药科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118777449-A | Method for separating and detecting related substances in benzyl-2-bromoethyl ether serving as starting material of ubenimex based on gas chromatography and liquid chromatography | 山东泰合医药科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-115925588-A | Preparation method of aliphatic sulfinic acid sodium salt | 诚达药业股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-114736201-B | Preparation method of umeclidinium bromide intermediate | 奥锐特药业(天津)有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-114736201-A | Preparation method of umeclidinium bromide intermediate | 奥锐特药业(天津)有限公司 | 2022-07-12 | — | — | CN | claimed |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| CN-119841765-A | DNJ derivative, pharmaceutical composition and application thereof | 中南大学 | 2025-04-18 | — | — | CN | disclosed |
| US-12246014-B2 | Azetidine derivatives | LIGAND UK DEVELOPMENT LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-119371430-A | Camptothecins small molecule and antibody drug conjugate, preparation method and application thereof | 上海医药集团股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118777449-B | Method for separating and detecting related substances in benzyl-2-bromoethyl ether serving as starting material of ubenimex based on gas chromatography and liquid chromatography | 山东泰合医药科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118777449-B | Method for separating and detecting related substances in benzyl-2-bromoethyl ether serving as starting material of ubenimex based on gas chromatography and liquid chromatography | 山东泰合医药科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118777449-B | Method for separating and detecting related substances in benzyl-2-bromoethyl ether serving as starting material of ubenimex based on gas chromatography and liquid chromatography | 山东泰合医药科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-6573378-B1 | 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine having a purity of greater than 95% by weight or it's sodium salt | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-06-03 | — | — | US | disclosed |
| EP-1309551-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | EP | disclosed |
| US-6407096-B1 | 1,4-BENZOTHIAZINE AND 1,4-BENZOXAZINE DERIVATIVES; HYPOTENSIVE, ANTIISCHEMIC, ANTIALLERGEN, ANTIASTHMATIC AND ANTICOAGULANT AGENTS; CARDIOVASCULAR DISORDERS | TORAY INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| WO-2002014273-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-21 | — | — | WO | disclosed |
| EP-1028113-A1 | FUSED BENZENE HETEROCYCLE DERIVATIVES AND UTILIZATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2000-08-16 | — | — | EP | disclosed |
| US-5075445-A | GUANINE DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1991-12-24 | — | — | US | disclosed |
| EP-0141927-B1 | ANTIVIRAL GUANINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0141927-A2 | Antiviral guanine derivatives | BEECHAM GROUP PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246014-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | EPHX1 233/4885TSHR 2185/4885TAAR1 255/4885 |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | EPHX1 1903/4885TSHR 4291/4885TAAR1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.